Collectively, our results demonstrate that the treatment with inhibitors targeting FcγRIIa, SERT, or complement anaphylatoxins successfully prevent thrombus formation in mice injected with spike-expressing human MKs, which were characterized by a high level of afucosylated anti-spike IgG antibodies, a marker of COVID-19 severity [4,5,6], thus revealing potential therapeutic targets that might prevent severe forms of the disease. The gene discussed is SLC6A4; the disease is COVID-19.